{"groups":[{"description":"HIPEC + 40 milligrams (mg) of Mitomycin C. Mitomycin C, 30 mg, were administered into the inflow line of the perfusion circuit once target temperature was reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, was administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period had elapsed, the perfusate was drained into the waste reservoir. The peritoneal cavity was rinsed/washed-out.\n\nhyperthermic intraperitoneal chemotherapy (HIPEC)\n\nMitomycin C","id":"FG000","title":"HIPEC + Mitomycin C"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"17"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Not Evaluable (Surgery and/or Treatment aborted but still enrolled)"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"51"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were recruited at 1 clinical site between early 2011 and March 2020. The first participant was enrolled into the study in November 2011."}